e-therapeutics (LSE: ETX)

Last close As at 21/11/2024

10.03

0.08 (0.80%)

Market capitalisation

59m

Edison Investment Research is terminating coverage on e-therapeutics (ETX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | edison tv

e-therapeutics showcase

Healthcare | Update

e-therapeutics — More to come in RNAi therapy discovery

Healthcare | Initiation

e-therapeutics — Enhancing siRNA drug discovery with LLMs

e-therapeutics

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (20.0) (39.3) (29.5)
Relative (21.3) (42.4) (29.6)
52 week high/low 23.1p/8.1p

Financials

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jan Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.5 (9.4) (9.5) (1.65) N/A N/A
2023A 0.5 (9.8) (9.8) (1.54) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free